Five hidden risks in early-phase OSD formulation development

Learn how to avoid critical mistakes in OSD formulation development that may initially speed FIH timelines, but do so at the expense of disrupting downstream regulatory, stability, and scalability processes

Reducing long-term risk

Tap into quick insights from Pharma Ignite and Thermo Fisher Scientific on supporting long-term success by dodging common early decision-making mistakes.

Read the article to learn more about the risks and opportunities in:

Understanding API complexity
Choosing the dosage form
Considering scalability
Estimating regulatory and stability factors
Adopting a holistic approach to decision making

Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.

By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).